Perspective Therapeutics CATX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -35.2%-2.1pp | -41.4%+1.9pp | -37.1%-7.2pp | -31.3%-5.1pp | -33.1%+0.5pp | |
| Return on invested capital | -44.3%+15.3pp | -55%+5.2pp | -73.1%— | -65.7%— | -59.6%— | |
| Liquidity | ||||||
| Current ratio | 8.7×-8.3× | 5.2×-7.5× | 8.7×-0.9× | 15.1×-12.6× | 17×+4.0× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $3.35-14.8% | $2.80-37.8% | $3.26-29.9% | $3.58-30.0% | $3.93-15.3% | |
| Valuation | ||||||
| Market capitalization | $342.14M+33.2% | $204.43M-5.2% | $254.72M-71.7% | $283.55M-57.8% | $157.73M-77.4% | |
| Price / book | 1×+0.1× | 1×+0.2× | 1.1×-1.7× | 1.1×-0.9× | 0.6×-2.5× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Perspective Therapeutics's profit margins?
- Perspective Therapeutics (CATX) runs a 33.1% gross margin and a -292.7% operating margin, with a -218.4% net margin.
- Where do Perspective Therapeutics's ratios come from?
- Every ratio is computed from Perspective Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
